{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:19Z","timestamp":1785860299958,"version":"3.56.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s43440-026-00879-x","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:33:38Z","timestamp":1784712818000},"page":"1022-1044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022\u20132024"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2416-6039","authenticated-orcid":false,"given":"Piotr","family":"Ryszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-2656","authenticated-orcid":false,"given":"Marta","family":"Baranowska-Kuczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-8153","authenticated-orcid":false,"given":"Barbara","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-6998","authenticated-orcid":false,"given":"Eberhard","family":"Schlicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"879_CR1","doi-asserted-by":"publisher","first-page":"1419110","DOI":"10.3389\/fphar.2024.1419110","volume":"15","author":"SM Stefan","year":"2024","unstructured":"Stefan SM, Rafehi M. Medicinal polypharmacology\u2014a scientific glossary of terminology and concepts. Front Pharmacol. 2024;15:1419110. https:\/\/doi.org\/10.3389\/fphar.2024.1419110.","journal-title":"Front Pharmacol"},{"issue":"3","key":"879_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11095-024-03656-8","volume":"41","author":"M Rafehi","year":"2024","unstructured":"Rafehi M, Moller M, Ismail Al-Khalil W, Stefan SM. Medicinal polypharmacology in the clinic \u2013 translating the polypharmacolome into therapeutic benefit. Pharm Res. 2024;41(3):411\u201317. https:\/\/doi.org\/10.1007\/s11095-024-03656-8.","journal-title":"Pharm Res"},{"key":"879_CR3","doi-asserted-by":"publisher","first-page":"108075","DOI":"10.1016\/j.bioorg.2024.108075","volume":"154","author":"AE Shaaban","year":"2025","unstructured":"Shaaban AE, Ali AR, Ayyad SN, Badria FA. Multi-target directed ligands inspired natural products as an effective approach for the treatment of complex chronic health disorders. Bioorg Chem. 2025;154:108075. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108075.","journal-title":"Bioorg Chem"},{"key":"879_CR4","doi-asserted-by":"publisher","first-page":"107247","DOI":"10.1016\/j.ejps.2025.107247","volume":"214","author":"AMK El-Sagheir","year":"2025","unstructured":"El-Sagheir AMK, Wenzel M, Yli-Kauhaluoma J. Fluoroquinolones as versatile scaffolds: potential for targeting classical and novel mechanisms to combat antibacterial resistance. Eur J Pharm Sci. 2025;214:107247. https:\/\/doi.org\/10.1016\/j.ejps.2025.107247.","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"879_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","volume":"22","author":"M Ge","year":"2025","unstructured":"Ge M, Chen XY, Huang P, Fleishman JS, Yang DH, Wu ZX, et al. Understanding and overcoming multidrug resistance in cancer. Nat Rev Clin Oncol. 2025;22(10):760\u201380. https:\/\/doi.org\/10.1038\/s41571-025-01059-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"879_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","volume":"22","author":"A Doostmohammadi","year":"2024","unstructured":"Doostmohammadi A, Jooya H, Ghorbanian K, Gohari S, Dadashpour M. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal. 2024;22(1):228. https:\/\/doi.org\/10.1186\/s12964-024-01607-9.","journal-title":"Cell Commun Signal"},{"issue":"14","key":"879_CR7","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.3390\/ijms26146996","volume":"26","author":"M Abdelsayed","year":"2025","unstructured":"Abdelsayed M. AI-driven polypharmacology in small-molecule drug discovery. IJMS. 2025;26(14):6996. https:\/\/doi.org\/10.3390\/ijms26146996.","journal-title":"IJMS"},{"issue":"5","key":"879_CR8","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1007\/s00210-024-03625-3","volume":"398","author":"CP Joshi","year":"2025","unstructured":"Joshi CP, Baldi A, Kumar N, Pradhan J. Harnessing network pharmacology in drug discovery: an integrated approach. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025;398(5):4689\u2013703. https:\/\/doi.org\/10.1007\/s00210-024-03625-3.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"879_CR9","doi-asserted-by":"publisher","unstructured":"Singh S, Kumar R, Payra S, Singh SK. Artificial intelligence and machine learning in pharmacological research: bridging the gap between data and drug discovery. Cureus. 2023;15(8):e44359. https:\/\/doi.org\/10.7759\/cureus.44359.","DOI":"10.7759\/cureus.44359"},{"issue":"23","key":"879_CR10","doi-asserted-by":"publisher","first-page":"11443","DOI":"10.3390\/ijms262311443","volume":"26","author":"SI Kang","year":"2025","unstructured":"Kang SI, Shin JH, Wu BM, Choi HS. Deep generative AI for multi-target therapeutic design: toward self-improving drug discovery framework. IJMS. 2025;26(23):11443. https:\/\/doi.org\/10.3390\/ijms262311443.","journal-title":"IJMS"},{"key":"879_CR11","doi-asserted-by":"publisher","first-page":"116540","DOI":"10.1016\/j.ejmech.2024.116540","volume":"275","author":"NR Brauer","year":"2024","unstructured":"Brauer NR, Kempen AL, Hernandez D, Sintim HO. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors. Eur J Med Chem. 2024;275:116540. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116540.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"879_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s43440-023-00501-4","volume":"75","author":"P Ryszkiewicz","year":"2023","unstructured":"Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: promises and new drugs in 2022. Pharmacol Rep. 2023;75(4):755\u201370. https:\/\/doi.org\/10.1007\/s43440-023-00501-4.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"879_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-025-00715-8","volume":"77","author":"P Ryszkiewicz","year":"2025","unstructured":"Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: new drugs in 2023\u20132024. Pharmacol Rep. 2025;77(3):543\u201360. https:\/\/doi.org\/10.1007\/s43440-025-00715-8.","journal-title":"Pharmacol Rep"},{"key":"879_CR14","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/j.phrs.2021.106055","volume":"176","author":"A Kabir","year":"2022","unstructured":"Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176:106055. https:\/\/doi.org\/10.1016\/j.phrs.2021.106055.","journal-title":"Pharmacological Res"},{"issue":"5","key":"879_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2023.2219892","volume":"22","author":"S Crisafulli","year":"2023","unstructured":"Crisafulli S, Khan Z, Karatas Y, Tuccori M, Trifiro G. An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting. Expert Opin Drug Saf. 2023;22(5):373\u201380. https:\/\/doi.org\/10.1080\/14740338.2023.2219892.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"879_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","volume":"25","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2024;25(6):979\u201397. https:\/\/doi.org\/10.1007\/s10198-023-01639-x.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"879_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14740338.2025.2575099","volume":"25","author":"D Leveque","year":"2026","unstructured":"Leveque D. The importance and utility of post market drug safety monitoring in cancer therapy. Expert Opin Drug Saf. 2026;25(5):823\u201335. https:\/\/doi.org\/10.1080\/14740338.2025.2575099.","journal-title":"Expert Opin Drug Saf"},{"key":"879_CR18","unstructured":"National comprehensive cancer network: NCCN guidelines for Patients\u00ae \u201cinvasive breast cancer\u201d. https:\/\/www.nccn.org. Accessed\u00a018 May 2026."},{"issue":"1","key":"879_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/antib15010005","volume":"15","author":"HV Giles","year":"2026","unstructured":"Giles HV, Kishore B. Bispecific antibodies: strategies available to optimize their safe delivery in patients with multiple myeloma. Antibodies (Basel). 2026;15(1):5. https:\/\/doi.org\/10.3390\/antib15010005.","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"879_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifiro G, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15\u201332. https:\/\/doi.org\/10.1007\/s40263-023-01059-8.","journal-title":"CNS Drugs"},{"key":"879_CR21","doi-asserted-by":"publisher","first-page":"1707211","DOI":"10.3389\/fimmu.2025.1707211","volume":"16","author":"X Lin","year":"2026","unstructured":"Lin X, Qin N, He B, Chen J, Zhang Y, Wang H, et al. Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS. Front Immunol. 2026;16:1707211. https:\/\/doi.org\/10.3389\/fimmu.2025.1707211.","journal-title":"Front Immunol"},{"key":"879_CR22","unstructured":"U.S. Department of Health and Human Services: common terminology criteria for adverse events (CTCAE) v6.0 (MedDRA 28.0). https:\/\/www.hhs.gov. Accessed\u00a018 May 2026."},{"issue":"1","key":"879_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12967-025-06709-7","volume":"23","author":"E Singh","year":"2025","unstructured":"Singh E, Bisserier M. Experimental animal models and patient-derived platforms to bridge preclinical discovery and translational therapeutics in pulmonary arterial hypertension. J Transl Med. 2025;23(1):665. https:\/\/doi.org\/10.1186\/s12967-025-06709-7.","journal-title":"J Transl Med"},{"issue":"3","key":"879_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40290-025-00561-2","volume":"39","author":"J Warner","year":"2025","unstructured":"Warner J, Prada Jardim A, Albera C. Artificial intelligence: applications in pharmacovigilance signal management. Pharm Med. 2025;39(3):183\u201398. https:\/\/doi.org\/10.1007\/s40290-025-00561-2.","journal-title":"Pharm Med"},{"issue":"9","key":"879_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/17460441.2024.2376643","volume":"19","author":"L Manen-Freixa","year":"2024","unstructured":"Manen-Freixa L, Antolin AA. Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery. Expert Opin Drug Discov. 2024;19(9):1043\u201369. https:\/\/doi.org\/10.1080\/17460441.2024.2376643.","journal-title":"Expert Opin Drug Discov"},{"key":"879_CR26","unstructured":"Verband Forschender Arzneimittelhersteller e.V.: Innovationsbilanz 2025. Innovation report 2025. 2025. https:\/\/www.vfa.de\/de\/forschung-entwicklung\/meilensteine-und-neueinfuehrungen\/innovationsbilanz-2025. Accessed 15 Apr 2026."},{"key":"879_CR27","unstructured":"Pharmazeutische Zeitung: Arzneistoffe. Jahr 2025 [Drugs. Year 2025]. 2025. https:\/\/www.pharmazeutische-zeitung.de\/arzneistoff-jahrgang\/jahr\/2025\/. Accessed 22 May 2026."},{"issue":"7","key":"879_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-025-02185-x","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA. Datopotamab deruxtecan: first approval. Drugs. 2025;85(7):965\u201375. https:\/\/doi.org\/10.1007\/s40265-025-02185-x.","journal-title":"Drugs"},{"key":"879_CR29","unstructured":"European Medicines Agency: Datroway\u00ae (datopotamab deruxtecan) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/datroway-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"18","key":"879_CR30","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Tisotumab vedotin: first approval. Drugs. 2021;81(18):2141\u201347. https:\/\/doi.org\/10.1007\/s40265-021-01633-8.","journal-title":"Drugs"},{"key":"879_CR31","unstructured":"European Medicines Agency: Tivdak\u00ae (tisotumab vedotin) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tivdak-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"10","key":"879_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40265-025-02207-8","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee A. Linvoseltamab: first approval. Drugs. 2025;85(10):1329\u201333. https:\/\/doi.org\/10.1007\/s40265-025-02207-8.","journal-title":"Drugs"},{"key":"879_CR33","unstructured":"European Medicines Agency: Lynozyfic\u00ae (linvoseltamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynozyfic-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"7","key":"879_CR34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3324\/haematol.2024.285343","volume":"110","author":"AG Minson","year":"2025","unstructured":"Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica. 2025;110(7):1483\u201399. https:\/\/doi.org\/10.3324\/haematol.2024.285343.","journal-title":"Haematologica"},{"key":"879_CR35","unstructured":"European Medicines Agency: Ordspono\u00ae (odronextamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ordspono-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"key":"879_CR36","unstructured":"European Medicines Agency: Augtyro\u00ae (repotrectinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/augtyro-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"2","key":"879_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Repotrectinib: first approval. Drugs. 2024;84(2):239\u201346. https:\/\/doi.org\/10.1007\/s40265-023-01990-6.","journal-title":"Drugs"},{"key":"879_CR38","unstructured":"European Medicines Agency: Balversa\u00ae (erdafitinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/balversa-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"key":"879_CR39","unstructured":"European Medicines Agency: Ezmekly\u00ae (mirdametinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ezmekly-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"7","key":"879_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-025-02190-0","volume":"85","author":"SM Hoy","year":"2025","unstructured":"Hoy SM. Mirdametinib: first approval. Drugs. 2025;85(7):977\u201384. https:\/\/doi.org\/10.1007\/s40265-025-02190-0.","journal-title":"Drugs"},{"issue":"2","key":"879_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-024-02136-y","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA. Inavolisib: first approval. Drugs. 2025;85(2):271\u201378. https:\/\/doi.org\/10.1007\/s40265-024-02136-y.","journal-title":"Drugs"},{"key":"879_CR42","unstructured":"European Medicines Agency: Itovebi\u00ae (inavolisib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/itovebi-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"key":"879_CR43","unstructured":"European Medicines Agency: Voranigo\u00ae (vorasidenib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/voranigo-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"10","key":"879_CR44","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","volume":"84","author":"YN Lamb","year":"2024","unstructured":"Lamb YN. Vorasidenib: First approval. Drugs. 2024;84(10):1325\u201331. https:\/\/doi.org\/10.1007\/s40265-024-02097-2.","journal-title":"Drugs"},{"key":"879_CR45","doi-asserted-by":"publisher","unstructured":"Boinpally R, Shebley M, Trugman JM. Atogepant: mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17(1):e13707. https:\/\/doi.org\/10.1111\/cts.13707.","DOI":"10.1111\/cts.13707"},{"key":"879_CR46","unstructured":"European Medicines Agency: Aquipta\u00ae (atogepant) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aquipta-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"key":"879_CR47","unstructured":"European Medicines Agency: Emcitate\u00ae (tiratricol) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emcitate-epar-product-information_en.pdf. Accessed\u00a025 May 2026."},{"issue":"8","key":"879_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40265-025-02197-7","volume":"85","author":"YN Lamb","year":"2025","unstructured":"Lamb YN. Tiratricol: first approval. Drugs. 2025;85(8):1059\u201365. https:\/\/doi.org\/10.1007\/s40265-025-02197-7.","journal-title":"Drugs"},{"issue":"1","key":"879_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Sig Transduct Target Ther. 2025;10(1):49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4.","journal-title":"Sig Transduct Target Ther"},{"key":"879_CR50","doi-asserted-by":"publisher","unstructured":"Riaz F, Gruber JJ, Telli ML. New treatment approaches for triple-negative breast cancer. Am Soc Clin Oncol Educ Book. 2025;45(3):e481154. https:\/\/doi.org\/10.1200\/EDBK-25-481154.","DOI":"10.1200\/EDBK-25-481154"},{"issue":"2","key":"879_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/ph19020324","volume":"19","author":"X Li","year":"2026","unstructured":"Li X, Liu J, Meng Y, Li J, Zhao J, Liu D, et al. Frontiers in antibody\u2013drug conjugates: mechanisms, design innovations, and clinical applications in targeted cancer therapy. Pharmaceuticals (Basel). 2026;19(2):324. https:\/\/doi.org\/10.3390\/ph19020324.","journal-title":"Pharmaceuticals (Basel)"},{"key":"879_CR52","doi-asserted-by":"publisher","first-page":"103096","DOI":"10.1016\/j.ctrv.2026.103096","volume":"144","author":"MI Alda","year":"2026","unstructured":"Alda MI, Grinda T, Pistilli B. Integrating antibody-drug conjugates into the management of early breast cancer. Cancer Treat Rev. 2026;144:103096. https:\/\/doi.org\/10.1016\/j.ctrv.2026.103096.","journal-title":"Cancer Treat Rev"},{"key":"879_CR53","doi-asserted-by":"publisher","first-page":"1495675","DOI":"10.3389\/fimmu.2024.1495675","volume":"15","author":"Y Tong","year":"2024","unstructured":"Tong Y, Fan X, Liu H, Liang T. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions. Front. Immunol. 2024;15:1495675. https:\/\/doi.org\/10.3389\/fimmu.2024.1495675.","journal-title":"Front. Immunol"},{"issue":"3","key":"879_CR54","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.esmoop.2022.100497","volume":"7","author":"S Michaleas","year":"2022","unstructured":"Michaleas S, Moreno Oliver A, Mueller-Berghaus J, Sarac SB, van der Elst ME, Muller-Egert S, et al. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer. ESMO Open. 2022;7(3):100497. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100497.","journal-title":"ESMO Open"},{"key":"879_CR55","doi-asserted-by":"publisher","first-page":"103023","DOI":"10.1016\/j.ctrv.2025.103023","volume":"140","author":"V Di Lauro","year":"2025","unstructured":"Di Lauro V, Rizzo A, Tafuro M, Fina E, Martinelli C, Calderaio C, et al. Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives. Cancer Treat Rev. 2025;140:103023. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103023.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"879_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/jcm15031079","volume":"15","author":"S Jouya","year":"2026","unstructured":"Jouya S, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee DY. Cervical cancer epidemiology: global incidence, mortality, survival, risk factors, and equity in HPV screening and vaccination. JCM. 2026;15(3):1079. https:\/\/doi.org\/10.3390\/jcm15031079.","journal-title":"JCM"},{"issue":"4","key":"879_CR57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/cancers18040563","volume":"18","author":"J Youssef","year":"2026","unstructured":"Youssef J, El Masri A, Atwi M, Ibrahim E, Salhab Z, Badawi M, et al. Molecular targets of cervical cancer and its microenvironment: advances in treatment. Cancers (Basel). 2026;18(4):563. https:\/\/doi.org\/10.3390\/cancers18040563.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"879_CR58","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","volume":"22","author":"AA Francoeur","year":"2025","unstructured":"Francoeur AA, Monk BJ, Tewari KS. Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol. 2025;22(3):182\u201399. https:\/\/doi.org\/10.1038\/s41571-024-00977-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"879_CR59","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/ijms27031439","volume":"27","author":"I Taritsa","year":"2026","unstructured":"Taritsa I, Fossel E. Pathways of resistance: modern multiple myeloma therapies and overcoming reliance on genomic integrity. IJMS. 2026;27(3):1439. https:\/\/doi.org\/10.3390\/ijms27031439.","journal-title":"IJMS"},{"key":"879_CR60","doi-asserted-by":"publisher","first-page":"101342","DOI":"10.1016\/j.blre.2025.101342","volume":"74","author":"X Zhou","year":"2025","unstructured":"Zhou X, Waldschmidt JM, Einsele H. Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies. Blood Rev. 2025;74:101342. https:\/\/doi.org\/10.1016\/j.blre.2025.101342.","journal-title":"Blood Rev"},{"issue":"2","key":"879_CR61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/ph19020320","volume":"19","author":"MMC Lopes","year":"2026","unstructured":"Lopes MMC, Xavier LDA, Nolasco S, Ribeiro SR, Coutinho DF, Sabino ADP. Next-generation biomarkers in multiple myeloma: advancing diagnosis, risk stratification, and precision therapy beyond current guidelines. Pharmaceuticals (Basel). 2026;19(2):320. https:\/\/doi.org\/10.3390\/ph19020320.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"879_CR62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/17474086.2026.2634283","volume":"19","author":"JA Lowy","year":"2026","unstructured":"Lowy JA, Rogers MF, Avigan ZM, Flores MS, Samuel M, Rattu MA, et al. Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen? Expert Rev Hematol. 2026;19(4):361\u201372. https:\/\/doi.org\/10.1080\/17474086.2026.2634283.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"879_CR63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14712598.2025.2465825","volume":"25","author":"ZM Avigan","year":"2025","unstructured":"Avigan ZM, Rattu MA, Richter J. An evaluation of linvoseltamab for treatment of relapsed\/refractory multiple myeloma. Expert Opin Biol Ther. 2025;25(3):221\u201328. https:\/\/doi.org\/10.1080\/14712598.2025.2465825.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"879_CR64","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/medicina62020342","volume":"62","author":"\u00c1 Jona","year":"2026","unstructured":"Jona \u00c1, Tothfalusi D, Illes \u00c1, Miltenyi Z. Bispecific antibodies in B-Cell lymphomas: mechanisms, efficacy, toxicity, and management. Medicina (Kaunas). 2026;62(2):342. https:\/\/doi.org\/10.3390\/medicina62020342.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"879_CR65","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/cancers18040701","volume":"18","author":"YE Ding","year":"2026","unstructured":"Ding YE, Zhong YR, Zhang LS, Xu L, Li J, Wen Y. Lipid metabolism reprogramming in diffuse large B-Cell lymphoma (DLBCL): mechanisms and treatment strategies. Cancers (Basel). 2026;18(4):701. https:\/\/doi.org\/10.3390\/cancers18040701.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"879_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3960\/jslrt.25050","volume":"65","author":"T Kobayashi","year":"2025","unstructured":"Kobayashi T. Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: recent advances and future prospects. JCEH. 2025;65(4):253\u201358. https:\/\/doi.org\/10.3960\/jslrt.25050.","journal-title":"JCEH"},{"key":"879_CR67","doi-asserted-by":"publisher","first-page":"1739598","DOI":"10.3389\/fonc.2026.1739598","volume":"16","author":"M Wespiser","year":"2026","unstructured":"Wespiser M, Gille R, Perol M. ROS1-positive non-small cell lung cancer: from genomics to treatment decisions. Front Oncol. 2026;16:1739598. https:\/\/doi.org\/10.3389\/fonc.2026.1739598.","journal-title":"Front Oncol"},{"issue":"11","key":"879_CR68","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/curroncol32110626","volume":"32","author":"H Bischoff","year":"2025","unstructured":"Bischoff H, Gendarme S, Somme L, Chouaid C, Schott R. Evolving therapeutic landscape of ROS1-positive non-small cell lung cancer: an updated review. Curr Oncol. 2025;32(11):626. https:\/\/doi.org\/10.3390\/curroncol32110626.","journal-title":"Curr Oncol"},{"key":"879_CR69","doi-asserted-by":"publisher","unstructured":"Desilets A, Repetto M, Yang SR, Drilon A. Targeting ROS1 rearrangements in non\u2013small cell lung cancer: current insights and future directions. Cancer. 2025;131(Suppl S1):e35784. https:\/\/doi.org\/10.1002\/cncr.35784.","DOI":"10.1002\/cncr.35784"},{"issue":"5","key":"879_CR70","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4111\/icu.20250008","volume":"66","author":"JJ Oh","year":"2025","unstructured":"Oh JJ, Hong SK. Contemporary management of metastatic urothelial carcinoma. Investig Clin Urol. 2025;66(5):375\u201382. https:\/\/doi.org\/10.4111\/icu.20250008.","journal-title":"Investig Clin Urol"},{"issue":"2","key":"879_CR71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","volume":"87","author":"R Li","year":"2025","unstructured":"Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, et al. FGFR inhibition in urothelial carcinoma. Eur Urology. 2025;87(2):110\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.012.","journal-title":"Eur Urology"},{"issue":"2","key":"879_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2025.5841","volume":"68","author":"J Du","year":"2025","unstructured":"Du J, Shen H, Zeng T, Liu W, Xie Y. Targeted therapies for urothelial carcinoma: from FGFR inhibitors to next\u2011generation antibody-drug conjugates (review). Int J Oncol. 2025;68(2):1\u201317. https:\/\/doi.org\/10.3892\/ijo.2025.5841.","journal-title":"Int J Oncol"},{"issue":"5","key":"879_CR73","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/ajhp\/zxz329","volume":"77","author":"K Roubal","year":"2020","unstructured":"Roubal K, Myint ZW, Kolesar JM. Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer. Am J Health-System Pharm. 2020;77(5):346\u201351. https:\/\/doi.org\/10.1093\/ajhp\/zxz329.","journal-title":"Am J Health-System Pharm"},{"issue":"23","key":"879_CR74","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.3390\/cancers17233788","volume":"17","author":"Y Lu","year":"2025","unstructured":"Lu Y, Xu M, Chen X, Xu H, Sun N, Weisgerber KE, et al. Neurofibromatosis type 1: genetic mechanisms and advances in therapeutic innovation. Cancers (Basel). 2025;17(23):3788. https:\/\/doi.org\/10.3390\/cancers17233788.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"879_CR75","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/13543784.2025.2558656","volume":"34","author":"G Oztosun","year":"2025","unstructured":"Oztosun G, Armstrong A, Hirbe AC. Mirdametinib, an FDA-approved MEK1\/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas. Expert Opin Investigational Drugs. 2025;34(9):665\u201373. https:\/\/doi.org\/10.1080\/13543784.2025.2558656.","journal-title":"Expert Opin Investigational Drugs"},{"key":"879_CR76","doi-asserted-by":"publisher","unstructured":"Phillips KA, Schiff D. Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas. Expert Rev Anticancer Ther. 2026;1\u20139. https:\/\/doi.org\/10.1080\/14737140.2026.2645395.","DOI":"10.1080\/14737140.2026.2645395"},{"key":"879_CR77","doi-asserted-by":"publisher","first-page":"1693927","DOI":"10.3389\/fimmu.2025.1693927","volume":"16","author":"R Zhu","year":"2025","unstructured":"Zhu R, Zhang H, Zhang F. Mechanistic optimization of inavolisib combined with CDK4\/6 inhibitors in the treatment of PIK3CA-mutated breast tumors. Front. Immunol. 2025;16:1693927. https:\/\/doi.org\/10.3389\/fimmu.2025.1693927.","journal-title":"Front. Immunol"},{"key":"879_CR78","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.ctrv.2024.102861","volume":"132","author":"C Hao","year":"2025","unstructured":"Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132:102861. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102861.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"879_CR79","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/biology13110885","volume":"13","author":"KA Choate","year":"2024","unstructured":"Choate KA, Pratt EPS, Jennings MJ, Winn RJ, Mann PB. IDH mutations in glioma: molecular, cellular, diagnostic, and clinical implications. Biol (Basel). 2024;13(11):885. https:\/\/doi.org\/10.3390\/biology13110885.","journal-title":"Biol (Basel)"},{"issue":"5","key":"879_CR80","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/noae259","volume":"27","author":"de la Fuente Mi","year":"2025","unstructured":"de la Fuente Mi, Touat M, van den Bent Mj, Preusser M, Peters KB, Young RJ, et al. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro-Oncology. 2025;27(5):1135\u201348. https:\/\/doi.org\/10.1093\/neuonc\/noae259.","journal-title":"Neuro-Oncology"},{"issue":"10","key":"879_CR81","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14656566.2025.2516617","volume":"26","author":"R Ruda","year":"2025","unstructured":"Ruda R, Bruno F, Pellerino A, Pronello E, Soffietti R. Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors. Expert Opin Pharmacother. 2025;26(10):1163\u201375. https:\/\/doi.org\/10.1080\/14656566.2025.2516617.","journal-title":"Expert Opin Pharmacother"},{"key":"879_CR82","doi-asserted-by":"publisher","unstructured":"Rossi J, Picca A, Santonocito OS, Schembari S, Testaverde L, Sanson M, et al. Advances in the management of patients with IDH-mutant glioma. Oncologist. 2025;30(12):oyaf391. https:\/\/doi.org\/10.1093\/oncolo\/oyaf391.","DOI":"10.1093\/oncolo\/oyaf391"},{"issue":"6","key":"879_CR83","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/CCO.0000000000001193","volume":"37","author":"A Seyve","year":"2025","unstructured":"Seyve A, Ducray F. Open questions on vorasidenib. Curr Opin Oncol. 2025;37(6):589\u201394. https:\/\/doi.org\/10.1097\/CCO.0000000000001193.","journal-title":"Curr Opin Oncol"},{"key":"879_CR84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-823357-3.00024-0","volume":"199","author":"E Caronna","year":"2024","unstructured":"Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention. Handb Clin Neurol. 2024;199:107\u201324. https:\/\/doi.org\/10.1016\/B978-0-12-823357-3.00024-0.","journal-title":"Handb Clin Neurol"},{"key":"879_CR85","doi-asserted-by":"publisher","first-page":"1708226","DOI":"10.3389\/fphar.2025.1708226","volume":"16","author":"B Jakubowska","year":"2025","unstructured":"Jakubowska B, Sowa-Kucma M. Gepants: targeting the CGRP pathway for migraine relief. Front Pharmacol. 2025;16:1708226. https:\/\/doi.org\/10.3389\/fphar.2025.1708226.","journal-title":"Front Pharmacol"},{"issue":"1","key":"879_CR86","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12883-025-04394-z","volume":"25","author":"NK Ladhwani","year":"2025","unstructured":"Ladhwani NK, Bai P, Lal R, Shah AM, Bai S, Ahmed GU, et al. The role of atogepant in migraine prevention: a systematic review and meta-analysis. BMC Neurol. 2025;25(1):375. https:\/\/doi.org\/10.1186\/s12883-025-04394-z.","journal-title":"BMC Neurol"},{"key":"879_CR87","doi-asserted-by":"publisher","first-page":"1444919","DOI":"10.3389\/fped.2024.1444919","volume":"12","author":"AJ Bauer","year":"2024","unstructured":"Bauer AJ, Auble B, Clark AL, Hu TY, Isaza A, McNerney KP, et al. Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review. Front Pediatr. 2024;12:1444919. https:\/\/doi.org\/10.3389\/fped.2024.1444919.","journal-title":"Front Pediatr"},{"key":"879_CR88","doi-asserted-by":"publisher","unstructured":"Markova B, Mayerl S, Heuer H. Toward a treatment for thyroid hormone transporter MCT8 deficiency \u2013 achievements and challenges. Eur Thyroid J. 2024;13(6):e240286. https:\/\/doi.org\/10.1530\/ETJ-24-0286.","DOI":"10.1530\/ETJ-24-0286"},{"key":"879_CR89","doi-asserted-by":"publisher","unstructured":"Garcia-Aldea \u00c1, Guillen-Yunta M, Valcarcel-Hernandez V, Montero-Pedrazuela A, Guadano-Ferraz A, Barez-Lopez S. Insights on the role of thyroid hormone transport in neurosensory organs and implication for the Allan\u2013Herndon\u2013Dudley syndrome. Eur Thyroid J. 2024;13(2):e230241. https:\/\/doi.org\/10.1530\/ETJ-23-0241.","DOI":"10.1530\/ETJ-23-0241"},{"issue":"4","key":"879_CR90","first-page":"4","volume":"171","author":"BM Gensthaler","year":"2026","unstructured":"Gensthaler BM, Gr\u00e4fe KA, R\u00f6\u00dfler A, Siebenand S. Die neuen Arzneistoffe 2025 [The new drugs 2025]. Pharm Ztg. 2026, Suppl. to 171(4):4\u201350.","journal-title":"Pharm Ztg"},{"key":"879_CR91","unstructured":"Gemeinsamer Bundesausschuss: benefit assessment of medicinal products. https:\/\/www.g-ba.de\/english\/benefitassessment\/. Accessed 11 May 2026."},{"key":"879_CR92","unstructured":"European Medicines Agency: Copiktra\u00ae (duvelisib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/copiktra. Accessed\u00a026 May 2026."},{"key":"879_CR93","doi-asserted-by":"publisher","first-page":"1378010","DOI":"10.3389\/fphar.2024.1378010","volume":"15","author":"P Long","year":"2024","unstructured":"Long P, Li S, Pan L, Wang Y, Chen W, Wang X. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Front Pharmacol. 2024;15:1378010. https:\/\/doi.org\/10.3389\/fphar.2024.1378010.","journal-title":"Front Pharmacol"},{"issue":"1","key":"879_CR94","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10120-024-01555-w","volume":"28","author":"H Kawakami","year":"2025","unstructured":"Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, et al. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025;28(1):51\u201361. https:\/\/doi.org\/10.1007\/s10120-024-01555-w.","journal-title":"Gastric Cancer"},{"key":"879_CR95","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.toxrep.2025.102054","volume":"14","author":"AZ Alrosan","year":"2025","unstructured":"Alrosan AZ, Dmour I, Rataan AO, Heilat GB, Alrosan K. Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: two recently developed chemotherapies in the crucial battle against breast cancer. Toxicol Rep. 2025;14:102054. https:\/\/doi.org\/10.1016\/j.toxrep.2025.102054.","journal-title":"Toxicol Rep"},{"issue":"3","key":"879_CR96","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","volume":"19","author":"S Cecco","year":"2024","unstructured":"Cecco S, Puligheddu S, Fusaroli M, Gerratana L, Yan M, Zamagni C, et al. Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System. Targ Oncol. 2024;19(3):435\u201345. https:\/\/doi.org\/10.1007\/s11523-024-01058-9.","journal-title":"Targ Oncol"},{"issue":"6","key":"879_CR97","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.21873\/invivo.14143","volume":"39","author":"Y Kanbayashi","year":"2025","unstructured":"Kanbayashi Y, Morioka R, Takayama K, Hosohata K. Disproportionality analysis of gastrointestinal adverse events associated with trastuzumab deruxtecan using the Japanese Adverse Drug Event Report database. In Vivo. 2025;39(6):3453\u201360. https:\/\/doi.org\/10.21873\/invivo.14143.","journal-title":"In Vivo"},{"key":"879_CR98","unstructured":"European Medicines Agency: Enhertu\u00ae (trastuzumab deruxtecan) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR99","doi-asserted-by":"publisher","first-page":"1397692","DOI":"10.3389\/fimmu.2024.1397692","volume":"15","author":"M Yu","year":"2024","unstructured":"Yu M, Zhou L, Cao M, Ji C, Zheng Y. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database. Front. Immunol. 2024;15:1397692. https:\/\/doi.org\/10.3389\/fimmu.2024.1397692.","journal-title":"Front. Immunol"},{"issue":"3","key":"879_CR100","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jaad.2025.10.134","volume":"94","author":"MM Kilton","year":"2026","unstructured":"Kilton MM, Wei EX, Georgeson CJ, Hirner JP. Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids. J Am Acad Dermatol. 2026;94(3):942\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.134.","journal-title":"J Am Acad Dermatol"},{"key":"879_CR101","unstructured":"European Medicines Agency: Padcev\u00ae (enfortumab vedotin) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/padcev-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"issue":"7","key":"879_CR102","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/14740338.2025.2471512","volume":"25","author":"X Fu","year":"2026","unstructured":"Fu X, Zeng D, Li M, Wu J, Yang Y, Mao Q, et al. Post-marketing safety surveillance of amivantamab: a real world study based on the FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2026;25(7):1309\u201317. https:\/\/doi.org\/10.1080\/14740338.2025.2471512.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"879_CR103","doi-asserted-by":"publisher","first-page":"9552","DOI":"10.1038\/s41598-024-55829-5","volume":"14","author":"R Sun","year":"2024","unstructured":"Sun R, Ning Z, Qin H, Zhang W, Teng Y, Jin C, et al. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA Adverse Event Reporting System (FAERS) database. Sci Rep. 2024;14(1):9552. https:\/\/doi.org\/10.1038\/s41598-024-55829-5.","journal-title":"Sci Rep"},{"key":"879_CR104","doi-asserted-by":"publisher","unstructured":"Zeng Y, Li Y, Du Z, Shu R, Fu C, Zeng Q. Cutaneous adverse events associated with rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024. Naunyn Schmiedebergs Arch Pharmacol. 2026. https:\/\/doi.org\/10.1007\/s00210-026-05168-1.","DOI":"10.1007\/s00210-026-05168-1"},{"issue":"1","key":"879_CR105","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12890-025-03509-z","volume":"25","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li W. Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. BMC Pulm Med. 2025;25(1):63. https:\/\/doi.org\/10.1186\/s12890-025-03509-z.","journal-title":"BMC Pulm Med"},{"key":"879_CR106","unstructured":"European Medicines Agency: Rybrevant\u00ae (amivantamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybrevant-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"issue":"7","key":"879_CR107","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","volume":"24","author":"X Le","year":"2025","unstructured":"Le X, Zhang Y, Ma J. Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert Opin Drug Saf. 2025;24(7):821\u201330. https:\/\/doi.org\/10.1080\/14740338.2025.2470875.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"879_CR108","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/ph17101266","volume":"17","author":"G Cicala","year":"2024","unstructured":"Cicala G, Russo G, Santoro V, Franchina T, Silvestris N, Santarpia M, et al. Neuropsychiatric adverse events with monoclonal antibodies approved for multiple myeloma: an analysis from the FDA Adverse Event Reporting System. Pharmaceuticals (Basel). 2024;17(10):1266. https:\/\/doi.org\/10.3390\/ph17101266.","journal-title":"Pharmaceuticals (Basel)"},{"key":"879_CR109","unstructured":"European Medicines Agency: Talvey\u00ae (talquetamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR110","unstructured":"European Medicines Agency: Tecvayli\u00ae (teclistamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR111","unstructured":"European Medicines Agency: Elrexfio\u00ae (elranatamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR112","doi-asserted-by":"publisher","unstructured":"Zhou M, Jiang C, Su C. Exploration of adverse event profiles for glofitamab: a disproportionality analysis using the FDA Adverse Event Reporting System. PLoS One. 2025;20(11):e0336151. https:\/\/doi.org\/10.1371\/journal.pone.0336151.","DOI":"10.1371\/journal.pone.0336151"},{"key":"879_CR113","unstructured":"European Medicines Agency: Columvi\u00ae (glofitamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/columvi-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR114","unstructured":"European Medicines Agency: Tepkinly\u00ae (epcoritamab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepkinly-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR115","unstructured":"European Medicines Agency: Lunsumio\u00ae (mosunetuzumab) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lunsumio-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR116","unstructured":"European Medicines Agency: Kimmtrak\u00ae (tebentafusp) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kimmtrak-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR117","doi-asserted-by":"publisher","unstructured":"Xu Y, Wang D, Xu Y. A real-world pharmacovigilance study of fruquintinib based on the FDA Adverse Event Reporting System (FAERS) database. Cancer Med. 2025;14(21):e71352. https:\/\/doi.org\/10.1002\/cam4.71352.","DOI":"10.1002\/cam4.71352"},{"key":"879_CR118","doi-asserted-by":"publisher","unstructured":"Liu C, Zhang H. Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database. Med (Baltim). 2026;105(14):e48239. https:\/\/doi.org\/10.1097\/MD.0000000000048239.","DOI":"10.1097\/MD.0000000000048239"},{"key":"879_CR119","unstructured":"European Medicines Agency: Fruzaqla\u00ae (fruquintinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fruzaqla-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"issue":"1","key":"879_CR120","doi-asserted-by":"publisher","first-page":"26150","DOI":"10.1038\/s41598-025-11411-1","volume":"15","author":"P Li","year":"2025","unstructured":"Li P, Wu L, Song Z. Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database. Sci Rep. 2025;15(1):26150. https:\/\/doi.org\/10.1038\/s41598-025-11411-1.","journal-title":"Sci Rep"},{"key":"879_CR121","unstructured":"European Medicines Agency: Lytgobi\u00ae (futibatinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lytgobi-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"issue":"1","key":"879_CR122","doi-asserted-by":"publisher","first-page":"2647604","DOI":"10.1080\/09546634.2026.2647604","volume":"37","author":"J Zhan","year":"2026","unstructured":"Zhan J, Lei Z, Xu Y, Cen J, Tang X, Wan M. Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study. J Dermatolog Treat. 2026;37(1):2647604. https:\/\/doi.org\/10.1080\/09546634.2026.2647604.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"879_CR123","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/1346-8138.17886","volume":"52","author":"Y Huang","year":"2025","unstructured":"Huang Y, Ke C, Chen M. Safety assessment of ritlecitinib based on the FDA adverse event reporting system (FAERS) database: a real-world pharmacovigilance study. J Dermatol. 2025;52(10):1561\u201369. https:\/\/doi.org\/10.1111\/1346-8138.17886.","journal-title":"J Dermatol"},{"issue":"2","key":"879_CR124","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/ced\/llaf427","volume":"51","author":"C Altinoz Guney","year":"2026","unstructured":"Altinoz Guney C, Koc HA. Investigation of infection risk associated with janus kinase inhibitors: a pharmacovigilance analysis using the Food and Drug Administration\u2019s Adverse Event Reporting System database. Clin Exp Dermatol. 2026;51(2):226\u201335. https:\/\/doi.org\/10.1093\/ced\/llaf427.","journal-title":"Clin Exp Dermatol"},{"key":"879_CR125","unstructured":"European Medicines Agency: Litfulo\u00ae (ritlecitinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/litfulo-epar-product-information_en.pdf. Accessed\u00a026 May 2026."},{"key":"879_CR126","doi-asserted-by":"publisher","first-page":"1561937","DOI":"10.3389\/fphar.2025.1561937","volume":"16","author":"X Che","year":"2025","unstructured":"Che X, Zhu Y. Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA Adverse Event Reporting System (FAERS). Front Pharmacol. 2025;16:1561937. https:\/\/doi.org\/10.3389\/fphar.2025.1561937.","journal-title":"Front Pharmacol"},{"key":"879_CR127","doi-asserted-by":"publisher","first-page":"1469597","DOI":"10.3389\/fphar.2025.1469597","volume":"16","author":"Y Feng","year":"2025","unstructured":"Feng Y, Fa X, Wang Y, Zhang T, Sun X, Li F. A real-world disproportionality analysis of ripretinib data mining of the public version of FDA Adverse Event Reporting System. Front Pharmacol. 2025;16:1469597. https:\/\/doi.org\/10.3389\/fphar.2025.1469597.","journal-title":"Front Pharmacol"},{"key":"879_CR128","doi-asserted-by":"publisher","first-page":"1481114","DOI":"10.3389\/fphar.2025.1481114","volume":"16","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang L, Gong Q, Huang L, Yin C, Miao Y, et al. Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database. Front Pharmacol. 2025;16:1481114. https:\/\/doi.org\/10.3389\/fphar.2025.1481114.","journal-title":"Front Pharmacol"},{"key":"879_CR129","doi-asserted-by":"publisher","first-page":"1542315","DOI":"10.3389\/fonc.2025.1542315","volume":"15","author":"S Wang","year":"2025","unstructured":"Wang S, Chen H, Zhou Y, Chen J, Cao J. Safety assessment of ripretinib: a real-world adverse event analysis from the Food and Drug Administration Adverse Event Reporting System. Front Oncol. 2025;15:1542315. https:\/\/doi.org\/10.3389\/fonc.2025.1542315.","journal-title":"Front Oncol"},{"key":"879_CR130","doi-asserted-by":"publisher","first-page":"1608451","DOI":"10.3389\/fonc.2025.1608451","volume":"15","author":"Y Ma","year":"2025","unstructured":"Ma Y, Fan A, Wang Y, Xu S, Liu X, Yang J. Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA Adverse Event Reporting System. Front Oncol. 2025;15:1608451. https:\/\/doi.org\/10.3389\/fonc.2025.1608451.","journal-title":"Front Oncol"},{"key":"879_CR131","unstructured":"European Medicines Agency: Qinlock\u00ae (ripretinib) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qinlock-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR132","doi-asserted-by":"publisher","first-page":"1442490","DOI":"10.3389\/fpsyt.2024.1442490","volume":"15","author":"AR Eugene","year":"2024","unstructured":"Eugene AR. Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA Adverse Event Reporting System, 2017\u20132023. Front Psychiatry. 2024;15:1442490. https:\/\/doi.org\/10.3389\/fpsyt.2024.1442490.","journal-title":"Front Psychiatry"},{"issue":"11","key":"879_CR133","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","volume":"47","author":"I Caruso","year":"2024","unstructured":"Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest. 2024;47(11):2671\u201378. https:\/\/doi.org\/10.1007\/s40618-024-02441-z.","journal-title":"J Endocrinol Invest"},{"key":"879_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DHPS.S556918","volume":"18","author":"S Gu","year":"2026","unstructured":"Gu S. Adverse events associated with tirzepatide: updated pharmacovigilance analysis using FAERS (2022 Q1-2025 Q1) with an adapted time-to-onset method. DHPS. 2026;18:1\u201313. https:\/\/doi.org\/10.2147\/DHPS.S556918.","journal-title":"DHPS"},{"issue":"2","key":"879_CR135","doi-asserted-by":"publisher","first-page":"101003","DOI":"10.1016\/j.trre.2026.101003","volume":"40","author":"LMA Correa","year":"2026","unstructured":"Correa LMA, Mazur GR, Santiago CBG, Dante LE, de Marco PS, Ferres PBS. Tirzepatide in solid organ transplant recipients: early real-world signals of efficacy and safety - a narrative review. Transpl Rev. 2026;40(2):101003. https:\/\/doi.org\/10.1016\/j.trre.2026.101003.","journal-title":"Transpl Rev"},{"issue":"18","key":"879_CR136","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/healthcare13182259","volume":"13","author":"HA Almansour","year":"2025","unstructured":"Almansour HA, Thaibah HA, Alfarhan M, Al-Qahtani SA, Khardali AA, Alshammari TM. Real-world safety concerns of tirzepatide: a retrospective analysis of FAERS data (2022\u20132025). Healthcare (Basel). 2025;13(18):2259. https:\/\/doi.org\/10.3390\/healthcare13182259.","journal-title":"Healthcare (Basel)"},{"key":"879_CR137","doi-asserted-by":"publisher","first-page":"1785129","DOI":"10.3389\/fphar.2026.1785129","volume":"17","author":"D Chen","year":"2026","unstructured":"Chen D, Wang Z, Xie Z, Chen Y, Luo S, Xu S. Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. Front Pharmacol. 2026;17:1785129. https:\/\/doi.org\/10.3389\/fphar.2026.1785129.","journal-title":"Front Pharmacol"},{"key":"879_CR138","doi-asserted-by":"publisher","unstructured":"Makkena HB. Comparative gynecological safety of the dual GIP\/GLP-1 receptor agonist tirzepatide vs. the GLP-1 receptor agonist semaglutide: a real-world pharmacovigilance analysis (2022\u20132025). Cureus. 2026;18(1):e101738. https:\/\/doi.org\/10.7759\/cureus.101738.","DOI":"10.7759\/cureus.101738"},{"key":"879_CR139","doi-asserted-by":"publisher","first-page":"119670","DOI":"10.1016\/j.jad.2025.119670","volume":"389","author":"M Wang","year":"2025","unstructured":"Wang M, Yang Z, Yan M, Liu S, Xiao S. Depression and suicide\/self-injury signals for weight loss medications: a disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database. J Affective Disord. 2025;389:119670. https:\/\/doi.org\/10.1016\/j.jad.2025.119670.","journal-title":"J Affective Disord"},{"issue":"21","key":"879_CR140","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.3390\/jcm14217678","volume":"14","author":"A Gandhi","year":"2025","unstructured":"Gandhi A, Bhatt N, Parhizgar A. Comparative renal safety of tirzepatide and semaglutide: an FDA Adverse Event Reporting System (FAERS)\u2014disproportionality study. JCM. 2025;14(21):7678. https:\/\/doi.org\/10.3390\/jcm14217678.","journal-title":"JCM"},{"issue":"3","key":"879_CR141","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11096-026-02099-y","volume":"48","author":"J Seijas-Amigo","year":"2026","unstructured":"Seijas-Amigo J, Salgado-Barreira \u00c1, Rodriguez-Penas D, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Manero M, et al. Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System. Int J Clin Pharm. 2026;48(3):1026\u201335. https:\/\/doi.org\/10.1007\/s11096-026-02099-y.","journal-title":"Int J Clin Pharm"},{"key":"879_CR142","doi-asserted-by":"publisher","first-page":"118731","DOI":"10.1016\/j.biopha.2025.118731","volume":"193","author":"SA Fahim","year":"2025","unstructured":"Fahim SA, Attia YM, Messiha A, Nabawy AY, Refaat F, El-Maadawy WH. Comparative safety and side effects of semaglutide and tirzepatide: implications for clinical decision-making in obesity management. Biomed Pharmacother. 2025;193:118731. https:\/\/doi.org\/10.1016\/j.biopha.2025.118731.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"879_CR143","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14740338.2025.2468860","volume":"24","author":"H Chen","year":"2025","unstructured":"Chen H, Ding Y, Shan Y. Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database. Expert Opin Drug Saf. 2025;24(8):959\u201367. https:\/\/doi.org\/10.1080\/14740338.2025.2468860.","journal-title":"Expert Opin Drug Saf"},{"key":"879_CR144","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","volume":"277","author":"M Lakhani","year":"2025","unstructured":"Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Nanji K, Xie JS, et al. Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries. Am J Ophthalmol. 2025;277:148\u201368. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.007.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"879_CR145","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/dom.16290","volume":"27","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Chinthammit C, Meeks A, Huang A, Ward JM, Mojdami D, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the optum market clarity database. Diabetes Obes Metab. 2025;27(5):2810\u201321. https:\/\/doi.org\/10.1111\/dom.16290.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"879_CR146","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/jdi.14340","volume":"16","author":"J Gong","year":"2025","unstructured":"Gong J, Gao F, Jiang K, Xie Q, Zhao X, Lei Z. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis. J Diabetes Invest. 2025;16(1):83\u201392. https:\/\/doi.org\/10.1111\/jdi.14340.","journal-title":"J Diabetes Invest"},{"issue":"5","key":"879_CR147","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41433-025-03718-0","volume":"39","author":"V Gregory","year":"2025","unstructured":"Gregory V, Mollan SP. Are synthetic incretins associated with ischaemic optic neuropathy? Eye (Lond). 2025;39(5):808\u201309. https:\/\/doi.org\/10.1038\/s41433-025-03718-0.","journal-title":"Eye (Lond)"},{"issue":"3","key":"879_CR148","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","volume":"143","author":"BJ Katz","year":"2025","unstructured":"Katz BJ, Lee MS, Lincoff NS, Abel AS, Chowdhary S, Ellis BD, et al. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol. 2025;143(3):215\u201320. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6058.","journal-title":"JAMA Ophthalmol"},{"key":"879_CR149","unstructured":"European Medicines Agency: Mounjaro\u00ae (tirzepatide) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mounjaro-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR150","doi-asserted-by":"publisher","first-page":"1693090","DOI":"10.3389\/fphar.2025.1693090","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu Y, Ke W, Li H. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for etrasimod. Front Pharmacol. 2025;16:1693090. https:\/\/doi.org\/10.3389\/fphar.2025.1693090.","journal-title":"Front Pharmacol"},{"issue":"1","key":"879_CR151","doi-asserted-by":"publisher","first-page":"36558","DOI":"10.1038\/s41598-025-19679-z","volume":"15","author":"Q Guo","year":"2025","unstructured":"Guo Q, Shan M, Gao W. Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database. Sci Rep. 2025;15(1):36558. https:\/\/doi.org\/10.1038\/s41598-025-19679-z.","journal-title":"Sci Rep"},{"key":"879_CR152","unstructured":"European Medicines Agency: Velsipity\u00ae (etrasimod) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/velsipity-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"issue":"9","key":"879_CR153","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s40620-025-02412-4","volume":"38","author":"H Fan","year":"2025","unstructured":"Fan H, Yang Y, Li J, Huang Z, Zhou B. Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS. J Nephrol. 2025;38(9):2881\u201391. https:\/\/doi.org\/10.1007\/s40620-025-02412-4.","journal-title":"J Nephrol"},{"issue":"1","key":"879_CR154","doi-asserted-by":"publisher","first-page":"2461668","DOI":"10.1080\/0886022X.2025.2461668","volume":"47","author":"W Fu","year":"2025","unstructured":"Fu W, Wang J, Xue Y, Pan D. Real-world assessment of sparsentan\u2019s drug safety framework. Ren Fail. 2025;47(1):2461668. https:\/\/doi.org\/10.1080\/0886022X.2025.2461668.","journal-title":"Ren Fail"},{"key":"879_CR155","doi-asserted-by":"publisher","unstructured":"Lv T, Bao W, Chen S. Assessing the real-world safety of sparsentan for immunoglobulin a nephropathy: insights from a comprehensive analysis of FAERS database. Int Urol Nephrol. 2026. https:\/\/doi.org\/10.1007\/s11255-026-05042-2.","DOI":"10.1007\/s11255-026-05042-2"},{"key":"879_CR156","unstructured":"European Medicines Agency: Filspari\u00ae (sparsentan) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/filspari-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR157","doi-asserted-by":"publisher","first-page":"1667249","DOI":"10.3389\/fimmu.2025.1667249","volume":"16","author":"L Wang","year":"2025","unstructured":"Wang L, Chen J, Li H, Wang L, Liu F, Jiang X. Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network. Front. Immunol. 2025;16:1667249. https:\/\/doi.org\/10.3389\/fimmu.2025.1667249.","journal-title":"Front. Immunol"},{"key":"879_CR158","unstructured":"European Medicines Agency: Zilbrysq\u00ae (zilucoplan) - summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zilbrysq-epar-product-information_en.pdf. Accessed\u00a027 May 2026."},{"key":"879_CR159","doi-asserted-by":"publisher","unstructured":"Rao M, Wu L, Chen H, Wu X, Wang H, Chen Y, et al. Hematological toxicity of anti-tumor antibody-drug conjugates: a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System. PLoS One. 2025;20(10):e0334513. https:\/\/doi.org\/10.1371\/journal.pone.0334513.","DOI":"10.1371\/journal.pone.0334513"},{"issue":"10","key":"879_CR160","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3390\/ph18101580","volume":"18","author":"M Marni","year":"2025","unstructured":"Marni M, Simoens D, Romero N, Jones WK, Kaja S. Disproportionality analysis of oral toxicities associated with PI3K\/AKT\/mTOR pathway inhibitors using the FAERS database. Pharmaceuticals (Basel). 2025;18(10):1580. https:\/\/doi.org\/10.3390\/ph18101580.","journal-title":"Pharmaceuticals (Basel)"},{"key":"879_CR161","doi-asserted-by":"publisher","unstructured":"Jin C, Zhang X, Ouyang X, Lou Q. Drug-induced urinary incontinence in pediatric patients: a disproportionality analysis of the FDA Adverse Event Reporting System. Med (Baltim). 2026;105(3):e47250. https:\/\/doi.org\/10.1097\/MD.0000000000047250.","DOI":"10.1097\/MD.0000000000047250"},{"issue":"1","key":"879_CR162","doi-asserted-by":"publisher","first-page":"185","DOI":"10.18240\/ijo.2026.01.23","volume":"19","author":"R Lischke","year":"2026","unstructured":"Lischke R, Rauchegger T, Haas G, Koubek M, Nowosielski Y, Rehak M, et al. Intraocular inflammation after intravitreal injection of faricimab\u2013a case series including one case of bilateral choroidal involvement. Int J Ophthalmol. 2026;19(1):185\u201392. https:\/\/doi.org\/10.18240\/ijo.2026.01.23.","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"879_CR163","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","volume":"7","author":"X Zhou","year":"2020","unstructured":"Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(7):581\u2013601. https:\/\/doi.org\/10.1016\/S2215-0366(20)30137-1.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"879_CR164","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1038\/s41467-025-59616-2","volume":"16","author":"YM Lin","year":"2025","unstructured":"Lin YM, Liao KM, Yu T, Wu JY, Lai CC. Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study. Nat Commun. 2025;16(1):4471. https:\/\/doi.org\/10.1038\/s41467-025-59616-2.","journal-title":"Nat Commun"},{"key":"879_CR165","doi-asserted-by":"publisher","unstructured":"Wen J, Syed B, Nadora D, How-Volkman C, Bernstein E, Truong A, et al. Tirzepatide versus semaglutide on weight loss in type 2 diabetes patients: a systematic review and meta-analysis of direct comparative studies. Endocrino Diabet Metabol. 2025;8(3):e70045. https:\/\/doi.org\/10.1002\/edm2.70045.","DOI":"10.1002\/edm2.70045"},{"key":"879_CR166","doi-asserted-by":"publisher","unstructured":"Aizpurua-Arruti X, Goyenechea E, Isla A, Onatibia-Astibia A, Malet-Larrea A, Gastelurrutia M, et al. Impact of additional monitoring on pharmacovigilance and pharmacists\u2019 role: a scoping review. Pharmacoepidemiol Drug. 2025;34(9):e70201. https:\/\/doi.org\/10.1002\/pds.70201.","DOI":"10.1002\/pds.70201"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00879-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:43Z","timestamp":1785856903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00879-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":166,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00879-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI or AI-assisted technologies were used in the preparation of this manuscript.","order":2,"name":"Ethics","label":"Disclosure of using artificial intelligence (AI) in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}